How do you think FDA's push for pharma to front costs for expedited ad approval is going to affect DTC spending in the next
year or two?
COMAN: Obviously, that's going to have a negative effect on pharma's ability to do more broad mass marketing. However, I think the
overall mindset is changing from mass commercialization and broad awareness to very specific personalized communications.
Everybody is sensitive to these regulations. This is a very regulated industry, and for decades we've been very careful in
terms of what we say and how we say it to make sure that the message is clear and that people are not overstepping boundaries.
And I think that there just continues to be more sensitivity around that into the future.
Brand Managers Downplay TV
Will there be another drastic change in the amount in the near future of money being spent on DTC?
COMAN: If you take a look at where we were historically, year after year there was a gradual increase in terms of sentiment to invest
more in broader channels. And to see such a dramatic shift from 2005 to 2006, I think that that's indicative of what's going
to happen into the future.